美国镭学会广泛期小细胞肺癌放疗适用标准
美国镭学会基于证据与改良德尔菲共识方法,由多学科专家组制定广泛期小细胞肺癌放疗适用标准。推荐无脑转移者可选择预防性颅脑照射或每3个月MRI监测,脑转移者行全脑放疗30 Gy/10次,选择性病例可考虑胸部巩固放疗30-54 Gy。
要点
- 无脑转移者可选预防性颅脑照射或每3个月MRI监测
- 脑转移者推荐全脑放疗30 Gy/10次
- 选择性病例可考虑胸部巩固放疗30-54 Gy
核心结论
- 放疗仍是广泛期小细胞肺癌治疗模式中不可或缺的组成部分。
研究设计与样本
- 美国镭学会适用标准为针对特定临床情况的循证指南,由多学科专家小组审阅。
- 指南包括对当前证据的回顾与分析,并应用共识方法(改良德尔菲法)对广泛期小细胞肺癌推荐治疗的适用性进行评分。
主要发现
- 当前证据支持对无脑转移证据的患者选择预防性颅脑照射或每3个月磁共振成像监测。
- 脑转移患者应接受全脑放疗,推荐剂量为30 Gy分10次。
- 胸部巩固放疗可在选择性病例中考虑,推荐剂量范围为30至54 Gy。
关键数值与推荐
- 无脑转移患者:预防性颅脑照射或每3个月MRI监测。
- 脑转移患者:全脑放疗30 Gy/10次。
- 选择性病例:胸部巩固放疗30-54 Gy,该推荐由专家意见驱动,因证据强度有限,相关临床试验仍在进行中。
临床怎么用
- 对无脑转移的广泛期小细胞肺癌患者,可在预防性颅脑照射与每3个月MRI监测之间选择。
- 对脑转移患者,采用全脑放疗30 Gy/10次。
- 对选择性病例,可考虑胸部巩固放疗30-54 Gy,但需注意证据强度有限。
局限性
- 胸部巩固放疗推荐由专家意见驱动,因证据强度有限,相关临床试验仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The standard-of-care therapy for extensive-stage SCLC has recently changed with the results of two large randomized trials revealing improved survival with the addition of immunotherapy to first-line platinum or etoposide chemotherapy. This has led to a lack of clarity around the role of consolidative thoracic radiation and prophylactic cranial irradiation in the setting of chemoimmunotherapy. METHODS: The American Radium Society Appropriate Use Criteria are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guidelines include a review and analysis of current evidence with the application of consensus methodology (modified Delphi) to rate the appropriateness of treatments recommended by the panel for extensive-stage SCLC. RESULTS: Current evidence supports either prophylactic cranial irradiation or surveillance with magnetic resonance imaging every 3 months for patients without evidence of brain metastases. Patients with brain metastases should receive whole-brain radiation with a recommended dose of 30 Gy in 10 fractions. Consolidative thoracic radiation can be considered in selected cases with the recommended dose ranging from 30 to 54 Gy; this recommendation was driven by expert opinion owing to the limited strength of evidence, as clinical trials addressing this question remain ongoing. CONCLUSIONS: Radiation therapy remains an integral component in the treatment paradigm for ES-SCLC.
引用
- Higgins KA, Simone CB, Amini A, et al. American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. J Thorac Oncol. 2020. PMID: 33011389. doi:10.1016/j.jtho.2020.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。